Global Insomnia Therapeutics Market Size study & Forecast, by Product (Drugs, Device) by Sales Channel (Prescription, Over-the-Counter (OTC))and Regional Analysis, 2022-2029

Global Insomnia Therapeutics Market Size study & Forecast, by Product (Drugs, Device) by Sales Channel (Prescription, Over-the-Counter (OTC))and Regional Analysis, 2022-2029

Global Insomnia Therapeutics Market is valued at approximately USD 2.8 billion in 2021and is anticipated to grow with a healthy growth rate of more than 5.3% over the forecast period 2022-2029.Insomnia Therapeutics is the treatment effective in preventing Insomnia. It is a sleep disorder that creates difficulty for the individual to fall or stay asleep. It is a very common disease prevailing these days and affecting a number of populations. There are several reasons for this disorder such as stress, poor sleep schedules, bad sleeping habits, anxiety and so on. It also affects mental health, work performance and quality of individual life. Additionally, increasing incidences of stress among individuals and the positive impact of COVID-19 on the insomnia market are driving the market for Insomnia Therapeutics.

The increasing stress levels among the global population due to several reasons lead to insomnia further driving the market for Insomnia Therapeutics. For instance, in 2022 50% of respondents were feeling more stressed than in the previousyear. In 2019 the percentage was just 38%. The stress can be due to workload, family issues, personal health care, and individual mental health. All age groups were affected due to this sleep disorder due to different reasons. The pandemic COVID-19 laid a positive impact on the Insomnia market. People suffered from stress due to job losses and unexpected situations. Such a deadly life event surged the demand for insomnia therapeutics in the market. Around 67% of respondents experienced higher levelsof stress during the pandemic globally in 2020. Moreover, the constant rise in hectic schedules of individuals, and continuous advancements and formulations in better insomnia treatment methods boosted the demand. However, the high cost of Insomnia Therapeutics stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Insomnia Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market for Insomnia therapeutics with a share of 54%. The growing geriatricc population and high prevalence of insomnia in this population is driving the market for Insomnia Therapeutics. The growing investments of key market players in R&D and innovations through frequent product launches play a major role in market demand. Asia-Pacific is expected to be the fastest-growing region due to increased stress and work schedules affecting sleep among the population is leading to insomnia disorders. The rising awareness to cure for sleep disorders is boosting the market demand.

Major market player included in this report are:
Takeda Pharmaceutical Company Ltd.;
Idorsia Pharmaceuticals Ltd
Eisai Co., Ltd.
Pfizer Inc.
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Electromedical Products International, Inc.
Paratek Pharmaceuticals, Inc.
Sumitomo Pharma Co., Ltd.

Recent Developments in the Market:
In May 2022, QUVIVIQ a medication to treat adult patients with insomnia launched by Idorsia Ltd received approval from European Commission. The symptoms should be for at least 3 months and impact daytime working.
In June 2021, DAYVIGO was launched by Eisai Co., Ltd., a global leader in life science products. This launch was to treat insomnia in adults. It was also approved by U.S. Food and Drug Administration (FDA).
Global Insomnia Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Sales Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporatespotential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
ByProduct:
Drugs
Device
By Sales Channel:
Prescription
Over-the-Counter (OTC)
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the WorldCompanies Mentioned
Takeda Pharmaceutical Company Ltd.;
Idorsia Pharmaceuticals Ltd
Eisai Co., Ltd.
Pfizer Inc.
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Electromedical Products International, Inc.
Paratek Pharmaceuticals, Inc.
Sumitomo Pharma Co., Ltd.


Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.